Loading
A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.
Grant McArthur is Executive Director of the Victorian Comprehensive Cancer Centre Alliance and a melanoma medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. He was a principal investigator for BRIM-3 and coBRIM, the trials that established BRAF inhibition with vemurafenib and combined BRAF and MEK inhibition with cobimetinib in melanoma. His publications include the extended follow-up of vemurafenib in BRAF V600E and V600K mutation-positive melanoma from BRIM-3. He has led translational programmes on resistance and on combining targeted therapy with immunotherapy, and now heads Victoria's cancer alliance.
| Title | Journal | Year |
|---|---|---|
| Safety and efficacy of vemurafenib in BRAF V600E and V600K mutation-positive melanoma (BRIM-3): extended follow-up | Lancet Oncology | 2014 |
| CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma | New England Journal of Medicine | 2025 |
Shares Cobimetinib, Vemurafenib.
Shares Cobimetinib, Vemurafenib.
Shares Vemurafenib, Melanoma.
Shares Vemurafenib, BRAF, Melanoma.
Shares Cobimetinib, Vemurafenib.
Shares Cobimetinib, Vemurafenib, BRAF, Melanoma.
Shares Peter MacCallum Cancer Centre, Melanoma.
Shares Cobimetinib, Melanoma.